Biognosys presents next-generation multiomics innovations at ASMS 2026

The Biognosys Group announced at the American Society for Mass Spectrometry (ASMS) 2026 conference in San Diego a series of advancements across its integrated proteomics and metabolomics portfolio.

The company introduced Spectronaut 21 and SpectroMine 6 for data-independent acquisition (DIA) and data-dependent acquisition (DDA) proteomics, highlighted a collaboration with SISCAPA Assay Technologies to advance ultra-sensitive targeted protein assays for clinical research , and presented optimized workflows for low-input proteomics, serum and plasma enrichment, FFPE tissue analysis, high-throughput nanoLC, and hybrid metabolomics.

These innovations aim to increase sensitivity, reproducibility, and throughput for discovery, translational, and clinical research worldwide.

Spectronaut 21 and SpectroMine 6 advance DIA and DDA proteomics

Biognosys has launched Spectronaut 21 and SpectroMine 6, setting new benchmarks in DIA and DDA proteomics data analysis. Across a cohort of 65 proteomics datasets, the software delivers approximately 10% more protein groups, while a cohort of 27 immunopeptidomics datasets shows around 11% more peptides identified.

These gains are enabled by advanced directDIA next-generation AI-driven post-translational modification (PTM) prediction, enhanced PTM localization and stoichiometry, and improved ion mobility metrics. Computational efficiency has been increased, with up to 15% faster processing of directDIA data, alongside new user-centric features for PTM and labeling workflows and open search capabilities for detecting rare modifications.

Biognosys and SISCAPA Assay Technologies collaborate on ultra-sensitive targeted proteomics

Biognosys and SISCAPA Assay Technologies (SAT) have formed a collaboration to advance ultra-sensitive targeted proteomics for clinical research applications. The partnership combines Biognosys’ expertise in proteomics and data analysis with SISCAPA’s peptide antibody enrichment technology for high-sensitivity absolute protein quantification.

As part of this collaboration, an ultrasensitive assay has been developed for quantifying UBE3A protein levels in human cerebrospinal fluid (CSF), supporting therapeutic research monitoring in patients with Angelman syndrome. This work underscores the potential of targeted proteomics to enable precise, clinically actionable biomarker measurements in neurological and other disease areas.

iST-S workflow delivers deep proteome coverage from ultra-low input samples

Biognosys has introduced iST-S, an optimized extension of the trusted PreOmics iST workflow, designed to enable high-throughput, reproducible deep proteomics from ultra-low input samples. The iST-S technology delivers affordable and highly reproducible proteomic depth from as little as 0.5 µg of starting material.

Internal benchmarking across diverse LC-MS platforms, including timsTOF HT and Orbitrap Astral, demonstrates consistent identification of approximately 7,500 protein groups across 0.5–10 µg inputs from HeLa and HEK293 cells. Peptide physicochemical properties are preserved, enabling reliable detection of proteins such as CDK9, HDAC1, and ERBB2 even at the lowest input levels.

Across commonly used cancer cell lines, iST-S enables up to 10,000 protein identifications with high reproducibility (coefficient of variation around 10%), supporting high-throughput, standardized low-input proteomics and large-scale screening applications.

P2 single-particle enrichment expands deep proteome coverage in serum and plasma

Biognosys has optimized its P2 single-particle enrichment technology for serum and alternative plasma matrices, extending the performance of protein corona-based enrichment beyond EDTA plasma. P2 leverages protein corona formation on a single engineered particle to enable reproducible, high-throughput enrichment in a single-well format.

Compared to the original P2-iST plasma kit and neat measurements, the optimized workflow demonstrates up to four-fold increased protein identifications in serum and heparin plasma, with robust quantitative performance. Linearity experiments show excellent correlation (R² up to approximately 0.97–0.98) across spike-in levels, supporting reliable quantification.

The P2 workflow shows robustness across plates, batches, laboratories, and blood collection methods, making it suitable for large-scale clinical proteomics studies.

Integrated LC-MS workflow enables scalable, high-depth FFPE tissue proteomics

Biognosys has developed an integrated end-to-end workflow for formalin-fixed, paraffin-embedded (FFPE) tissue proteomics, combining best-in-class sample preparation, separation, and data analysis. The workflow leverages PreOmics BeatBox and iST, paired with Bruker’s PepSep Advanced columns on the nanoElute 2 system, timsTOF, and Spectronaut, to enable scalable, high-throughput FFPE analysis from sample to result.

The plate-based workflow eliminates the need for deparaffinization, facilitating efficient processing of retrospective clinical cohorts. It supports diverse FFPE formats, including curls, punches, and microdissection, and enables identification of approximately 5,000 protein groups from as little as two FFPE curls. This makes the workflow well suited for large-scale biomarker discovery studies in oncology and other disease areas.

Enhanced PepSep nanoLC performance for high-throughput proteomics

Biognosys is advancing nanoLC performance through integration of the Bruker proteoElute LC system with PepSep Advanced columns, coupled to timsTOF and Spectronaut 21. This workflow supports robust, high-throughput proteomics with stable operation over extended acquisition periods of up to 12 days without intervention, maintaining retention time deviations below 1%.

High proteome depth is achieved with up to approximately 10,600 protein groups, depending on gradient length, while maintaining strong quantitative precision (coefficient of variation around 20%)

The system minimizes carry-over to below 1% even at high sample loads, supported by optimized wash strategies that reduce residual contamination. This enables reliable, reproducible analysis in demanding high-throughput environments such as core facilities and large-scale clinical studies.

Hybrid targeted and untargeted metabolomics with MxQuant kit on timsMetabo

Bruker and Biocrates are expanding standardized quantitative metabolomics with the introduction of the MxQuant kit and a preview of a novel hybrid metabolomics workflow on the timsMetabo platform. The workflow unifies quantitative targeted metabolomics with untargeted discovery in a single PASEF measurement, increasing depth while reducing complexity.

Biocrates’ quantitative kits are now also available for workflows using the EVOQ triple quadrupole, enabling standardized, kit-based targeted and absolute quantitation approaches within familiar LC-TQ-MS operations. This expands routine access to reproducible, comparable metabolomics data with integrated quality control and streamlined methods designed for scale across translational and applied research settings.

Biognosys is offering these targeted workflows in its Massachusetts laboratory as a contract research organization (CRO) service for biocrates targeted, absolute quantitative metabolomics. This CRO option enables high-quality quantitative metabolomics without the need for in-house method deployment, supporting rapid project start-up, capacity scaling, and standardized data generation for multi-site studies.

Bruker is previewing a hybrid metabolomics workflow that combines quantitative measurement enabled by biocrates kits with discovery on the timsMetabo platform in a single integrated experiment. This hybrid quantitation-plus-discovery approach addresses a central challenge in metabolomics: the need to combine standardized quantitative rigor with exploratory breadth without doubling sample consumption, instrument time, or method complexity, enabling deeper disease biology insights in population-scale translational research and exposomics.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>